THE USE OF THE AGENT FOR INDUCING IMMUNITY TO SARS-COV-2
The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. In addition the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. Furthermore, the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. The inventions provide effective induction of the immune response against SARS-CoV-2 virus in subjects above 60 years of age and also having chronic diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 27. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-27, Last update posted on www.tib.eu: 2024-03-26, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
EP4294439 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000957119 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000957119 | ||
| 003 | DE-627 | ||
| 005 | 20240329160058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000957119 | ||
| 035 | |a (EPA)EP4294439 | ||
| 035 | |a (EPA)82850909 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZUBKOVA OLGA VADIMOVNA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a THE USE OF THE AGENT FOR INDUCING IMMUNITY TO SARS-COV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-27, Last update posted on www.tib.eu: 2024-03-26, Last updated: 2024-03-29 | ||
| 520 | |a The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. In addition the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. Furthermore, the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. The inventions provide effective induction of the immune response against SARS-CoV-2 virus in subjects above 60 years of age and also having chronic diseases. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a OZHAROVSKAIA TATIANA ANDREEVNA |4 aut | |
| 700 | 0 | |a DOLZHIKOVA INNA VADIMOVNA |4 aut | |
| 700 | 0 | |a POPOVA OLGA |4 aut | |
| 700 | 0 | |a SHCHEBLIAKOV DMITRII VIKTOROVICH |4 aut | |
| 700 | 0 | |a GROUSOVA DARIA MIKHAILOVNA |4 aut | |
| 700 | 0 | |a DZHARULLAEVA ALINA SHAHMIROVNA |4 aut | |
| 700 | 0 | |a TUKHVATULIN AMIR ILDAROVICH |4 aut | |
| 700 | 0 | |a TUKHVATULINA NATALIA MIKHAILOVNA |4 aut | |
| 700 | 0 | |a SHCHERBININ DMITRII NIKOLAEVICH |4 aut | |
| 700 | 0 | |a ESMAGAMBETOV ILIAS BULATOVICH |4 aut | |
| 700 | 0 | |a TOKARSKAYA ELIZAVETA ALEXANDROVNA |4 aut | |
| 700 | 0 | |a BOTIKOV ANDREI GENNADIEVICH |4 aut | |
| 700 | 0 | |a EROKHOVA ALINA SERGEEVNA |4 aut | |
| 700 | 0 | |a IZHAEVA FATIMA MAGOMEDOVNA |4 aut | |
| 700 | 0 | |a NIKITENKO NATALIA ANATOLIEVNA |4 aut | |
| 700 | 0 | |a LUBENETS NADEZHDA LEONIDOVNA |4 aut | |
| 700 | 0 | |a SEMIKHIN ALEKSANDR SERGEEVICH |4 aut | |
| 700 | 0 | |a NARODITSKY BORIS SAVELIEVICH |4 aut | |
| 700 | 0 | |a LOGUNOV DENIS YURYEVICH |4 aut | |
| 700 | 0 | |a GINTSBURG ALEKSANDR LEONIDOVICH |4 aut | |
| 700 | 0 | |a CHERNETSOV VLADIMIR ALEKSANDROVICH |4 aut | |
| 700 | 0 | |a KRIUKOV EVGENII VLADIMIROVICH |4 aut | |
| 700 | 0 | |a BABIRA VLADIMIR FEDOROVICH |4 aut | |
| 700 | 0 | |a KUTAEV DMITRII ANATOLIEVICH |4 aut | |
| 700 | 0 | |a LOGINOVA SVETLANA YAKOVLEVNA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 27. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/82850909/publication/EP4294439A1?q=EP4294439 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 12 | ||